MEMPHIS, Tenn. -- A study outlining a new gene therapy treatment for Hemophilia, developed at Saint Jude’s in Memphis, appears in this month’s issue of the New England Journal of Medicine.
In a news release, St. Jude’s says the findings of a six-person study mark the first proof that gene therapy can reduce bleeding episodes for those suffering from the inherited blood disorder. Four of the six participants have reportedly had no bleeding episodes since undergoing the new therapy.
Dr. Andrew Davidoff is spokesman for St. Jude’s.
